BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development

Updated Date: Thu, 25 May 2023 00:00:00 EDT

The online version of this obituary (doi:10.1136/bmj.p695, published 23 March 2023) features a photograph of Traute Lafrenz, as […]

Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services

Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine […]

Scanning for pulmonary embolismWe all know that feeling when a colleague comes up to you with a grave […]

This is spinal tuberculosis on a midline T2 weighted sagittal magnetic resonance image of the spine of a […]

The studyBlom AW, Lenguerrand, Strange S, et al. Clinical and cost effectiveness of single stage compared with two […]

Looking young for your ageFacial ageing reflects ageing in other parts of the body. When high quality photographs […]

For too long, societies around the world have tended to see money that is spent on healthcare as […]